top of page
Advent Access Logo

Unlocking the Future of Dialysis

About Advent Access

About Advent Access

Advent Access is a medical technology startup focused on end-stage renal disease management. A Stanford StartX company and spin-off from A*STAR, Advent’s mission is to pioneer innovations to significantly reduce dialysis cost and improve quality of life for kidney failure patients.

The company’s 1st product is the av-Guardian™ - an award-winning implant technology that aims to improve vascular access reliability, enable less-painful cannulation and, in the long run, potentially reduce vascular access related hospitalizations. av-Guardian™ is CE Mark cleared device.


The company’s 2nd product is the Vwing™ - an implantable device designed to facilitate safe and reliable access to arteriovenous fistulas (AVF) in obese patients suffering from end stage renal disease undergoing hemodialysis. Vwing™ is US FDA 510(k) cleared device which is currently being used in the United States, Europe, and Canada





Enabling Vascular Access to Arteriovenous Fistulas (AVF) for Patients Undergoing Hemodialysis

VWING Picture 2.png
VWING Picture.png

The VWING is a patented subcutaneous needle guide that provides safe and reliable dialysis access sites in challenging to cannulate AV fistulas.


The VWING is a surgically placed vascular needle guide that is completely subcutaneous and extravascular. The VWING provides an easily palpable target for needle insertion and guides a dialysis needle directly to the targeted vessel, enabling the use of blunt needles via a guided constant site or “buttonhole” cannulation. Buttonhole cannulation technique has been shown in multiple clinical studies to reduce AV fistulae complications and improve long-term fistula durability and patency. However, the technique has not gained broad adoption due to practical challenges with clinical implementation. The VWING has demonstrated its ability to enable the use of buttonhole cannulation technique.

About av-Guardian

AVG pic 2.png
AVG pic.png

The av-Guardian™ is the world’s first medical device to pioneer the concept of having a “guardian guide-door” to 
optimally access an arteriovenous fistula (AVF) without being in contact with the dialysis vein. Fully embedded under the skin, the av-Guardian™ aims to provide a reliable and less-painful way to perform vascular access in order to enable hemodialysis to be a more comfortable therapy to sustain life. 

The award-winning implant technology represents the next generation vascular access system that further aims to simplify cannulation, and enable consistent hemodialysis cannulation to be performed across dialysis care environments.


Guardian guide-door to a patient’s lifeline

The Av-Guardian

As Seen On

Contact Us
bottom of page